Correlation between DKK-1 serum level and characteristics of ASAS+ patients of the DESIR cohort.

<p>ASDAS, Ankylosing Spondylitis Disease Activity Score</p><p>^a: Univariate analysis</p><p>^b: Multivariate analysis with hs-CRP, ESR, and ASDAS-ESR excluded</p><p>Correlation between DKK-1 serum level and characteristics of ASAS+ patients of the DESIR cohort.</p

Correlation of DKK-1 serum level with systemic inflammation assessed by ESR.

<p>(A) (r_s = 0.1, p = 0.03), CRP level (B) (r_s = 0.17; p = 0.0001), hs-CRP level (C) (r_s = 0.14; p = 0.003), Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR (D) (r_s = 0.11; p = 0.02) and ASDAS-CRP level (E) (r_s = 0.13; p = 0.004); r_s: Spearman correlation coefficient.</p

Correlation between SOST serum level and characteristics of ASAS+ patients of the DESIR cohort.

<p>^a: Univariate analysis</p><p>^b: Multivariate analysis with hs-CRP and ESR excluded</p><p>Correlation between SOST serum level and characteristics of ASAS+ patients of the DESIR cohort.</p

Serum sclerotin (SOST) level among patients with axial spondyloarthritis (SpA) and controls at baseline.

<p>Each point represents 1 patient. Data are mean ± SD. ***p<0.0001.</p

Correlation of SOST serum level with age.

<p>(A) (r_s = 0.36; p<0.0001), C-reactive protein (CRP) level (B) (r_s = -0.18; p = 0.0001), high-sensitivity CRP (hs-CRP) level (C) (r_s = -0.22; p<0.0001), erythrocyte sedimentation rate (ESR) (D) (r_s = -0.12, p = 0.007) and Dickkopf-1 (DKK-1) serum levels (E) (r_s = 0.15, p = 0.0008); r_s: Spearman correlation coefficient.</p

Baseline demographics and disease characteristics of Assessment of Spondyloarthritis International Society (ASAS+) patients from the DESIR cohort.

<p>Data are mean±SD unless indicated</p><p>HLA-B27, human leukocyte antigen B27; CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; ESR, erythrocyte sedimentation rate; BASDI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, nonsteroidal anti-inflammatory drugs; DKK-1, Dickkopf-1; SOST, sclerostin</p><p>Baseline demographics and disease characteristics of Assessment of Spondyloarthritis International Society (ASAS+) patients from the DESIR cohort.</p

Patients with active disease in the various ESSDAI domains at enrollment.

<p>Clinical involvement corresponding to each of these twelve domains is defined according to the ESSDAI (ref 6).</p

Characteristics associated with a history of lymphoma.

<p>Results are expressed as medians (25^th–75^th percentiles) unless otherwise specified.</p

Characteristics of patients at enrollment in the ASSESS cohort.

<p>Results are expressed as medians (25^th–75^th percentiles) unless otherwise specified. MTX: methotrexate; LEF: leflunomide; AZA: azathioprine; MMF: mycophenolate mofetil; RTX: rituximab; RF: rheumatoid factor.</p

Results of the GWAS meta-analysis of European RA case-control cohorts in the <i>PLB1</i> locus.

a<p>Based on NCBI Build 37/hg19.</p>b<p>Conditioned with rs116018341.</p>c<p>AA risk haplotype was not observed in the imputation reference panel.</p><p>RA; rheumatoid arthritis, ACPA; anti-citrullinated protein antibodies.</p